FUT9: A Promising Drug Target and Biomarker for Various Diseases

Target Name: FUT9

NCBI ID: G10690

FUT9: A Promising Drug Target and Biomarker for Various Diseases

FUT9 (fucT-IX) is a protein that is expressed in various tissues of the body, including the liver, spleen, and pancreas. It is a scaffold protein that plays a role in the structure and function of many different cell types. FUT9 has also been shown to be a potential drug target and biomarker for a variety of diseases.

The discovery of FUT9 comes from a research study by a team of scientists at the University of California, San Diego. The study, published in the journal Nature in 2018, identified FUT9 as a promising drug target for the treatment of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Since the publication of that study, researchers have continued to investigate the potential of FUT9 as a drug target. They have found that FUT9 is involved in a variety of cellular processes that are important for the development and progression of many different diseases.

One of the key functions of FUT9 is its role in the development of cancer. Many studies have shown that FUT9 is often overexpressed in cancer cells, and that this overexpression can contribute to the development and progression of cancer. Researchers are also exploring the potential of drugs that target FUT9 to treat various types of cancer.

In addition to its role in cancer, FUT9 is also involved in the development and progression of neurodegenerative diseases. Many of these diseases, such as Alzheimer's and Parkinson's, are characterized by the progressive loss of brain cells and the buildup of neurofibrillary tangles. FUT9 has been shown to be involved in the formation of these tangles, and researchers are exploring the potential of drugs that target FUT9 to treat these diseases.

FUT9 is also being investigated as a potential biomarker for a variety of diseases. Many diseases, including cancer, have no specific symptoms or diagnostic tests that can confirm their presence. However, researchers can use proteins like FUT9 as biomarkers to identify the presence of these diseases. For example, researchers can use FUT9 to diagnose neurodegenerative diseases, such as Alzheimer's and Parkinson's.

In conclusion, FUT9 is a protein that is expressed in various tissues of the body and has been shown to be involved in the development and progression of a variety of diseases. As a potential drug target and biomarker, FUT9 is a promising target for the development of new treatments for a wide range of diseases. Further research is needed to fully understand the role of FUT9 in these diseases and to develop effective treatments.

Protein Name: Fucosyltransferase 9

Functions: Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to the N-acetyl glucosamine (GlcNAc) of a distal lactosamine unit of a glycoprotein or a glycolipid-linked polylactosamine chains through an alpha-1,3 glycosidic linkage and participates in particular to the Lewis x (Lex)/CD15 epitope biosynthesis in neurons which allows cell differentiation, cell adhesion, and initiation of neurite outgrowth (PubMed:23263199, PubMed:23192350, PubMed:10386598, PubMed:17335083, PubMed:23000574, PubMed:11278338, PubMed:10622713, PubMed:18395013, PubMed:12107078, PubMed:16282604, PubMed:29593094). Also fucosylates di-, tri- and tetraantennary N-glycans linked to glycoproteins and the inner lactosamine unit of the alpha2,3-sialylated polylactosamine resulting in sLex (CD15s) epitope synthesis (PubMed:12107078, PubMed:18395013). Furthermore, it is capable of synthesizing Lewis a (Lea), although to a lesser extent than Lex and Lewis y (Ley) and to confer SELE-dependent, but not SELL- and SELP-selectin-dependent, cell rolling and adhesion by enhancing Lex and sLex synthesis (PubMed:18395013, PubMed:23192350). May also fucosylate the internal LacNAc unit of the polylactosamine chain to form VIM-2 antigen that serves as recognition epitope for SELE

More Common Targets